ThursdaySep 30, 2021 11:32 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Versatile DehydraTECH(TM) Technology Improving Taste, Bioabsorption, Efficacy of Drugs

Lexaria Bioscience is the global innovator behind the disruptive DehydraTECH(TM) drug delivery technology DehydraTECH’s taste-masking capabilities eliminate the need for unwanted sweeteners or chemical masking agents The technology also significantly increases the bioavailability of drugs, speeds up the rate of drug onset, and boosts brain absorption DehydraTECH presents numerous opportunities and has been evaluated in R&D programs featuring DehydraTECH-processed nicotine, antivirals, and cannabidiol  Oral delivery is the easiest and most convenient way to administer medications, yet it is prevalently associated with patient noncompliance owing to many drugs’ bitter taste. The problem appears widespread and necessitating remedial bitterness-masking interventions. But as…

Continue Reading

WednesdaySep 29, 2021 12:35 pm

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Pioneering the Growth of Cannabis-Infused Beverages

BevCanna Enterprises Inc. is a diversified health & wellness beverage and natural products company, which offers in-house brands and provides white-label production and distribution solutions to its industry-leading partners BevCanna has recently announced tie-ups with Keef Brands as well as with The Tinley Beverage Company to produce and distribute their products within the Canadian continent Functional drinks and drinks based on plant derivatives — particularly those containing cannabis- or hemp-derived ingredients like cannabidiol (“CBD”) or tetrahydrocannabinol (“THC”) — have rapidly established themselves as one of the fastest-growing verticals within the North American beverage industry, with a recent study forecasting the…

Continue Reading

FridaySep 24, 2021 9:30 am

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Ideally Situated in Burgeoning Cannabis Beverage Sector

EMR report projects that North America is likely to be fastest, largest marketplace for cannabis beverages Cannabis beverage industry projected to grow at CAGR of 48% in the next five years, reaching an anticipated $12.7 billion by 2026 BevCanna manufactures its own beverage product lines, offers white-label services to companies looking for the highest-quality products available North America will be a leader in the global cannabis beverage market, according to a recent Expert Market Research (“EMR”) report (https://cnw.fm/QAPcL). This projection bodes well for BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health & wellness beverage and natural products…

Continue Reading

FridaySep 24, 2021 9:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Solution for Faster and More Effective Drug Delivery

One of the main challenges with drug delivery and the overall effectiveness of the drugs is first-pass metabolism/excretion  Lexaria solves this problem with its DehydraTECH(TM) drug delivery technology Since the company began working on this technology back in 2014, it has made major strides in the delivery of hypertension and anti-viral treatments Since its inception, Lexaria Bioscience (NASDAQ: LEXX) has remained committed to enhancing the speed and overall efficiency of orally delivered fat-soluble active molecules in drugs. With its drug delivery technology, DehydraTECH(TM), the company has aided in developing hypertension and anti-viral treatments (https://cnw.fm/xwiio). This is a big achievement for…

Continue Reading

WednesdaySep 22, 2021 9:15 am

Flora Growth Corp. (NASDAQ: FLGC) Makes Early Leap into Expected Opening of Cannabis Trade in Panama

Flora Growth Corp., a cannabis company with low-cost cultivation and global distribution, recently reached a non-binding LOI with Panamanian importer and distributor Robust Farms Inc. to supply product from its portfolio   Panama is a country on the verge of opening to medical marijuana sales and the first in Central America to open a regulated market following legislation approved without a dissenting vote by the National Assembly Flora Growth maintains a large licensed outdoor operation in Colombia, from which it cultivates cannabis that will be used in a variety of branded products  Flora Growth has been increasing its international outlets, including…

Continue Reading

FridaySep 17, 2021 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Signs Definitive Agreement to Acquire 100% of BayMedica Inc., Positioning it to Stand Distinct in Rare Cannabinoids Manufacturing, Become a Revenue-Generating Company, Expand Drug Development Capabilities

InMed Pharmaceuticals recently announced it has entered a definitive agreement to acquire 100% of BayMedica Inc. BayMedica is a private company that specializes in the manufacture and commercialization of rare cannabinoids Upon closing, the transaction will make InMed a global leader in the manufacturing of rare cannabinoids in addition to transforming it into a revenue-generating company Acquisition provides InMed with the complete flexibility across multiple manufacturing approaches On September 13, InMed Pharmaceuticals (NASDAQ: INM), a company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids, announced it has signed a definitive agreement to acquire 100% of BayMedica…

Continue Reading

FridaySep 17, 2021 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Draws Closer to NDA Filing for DehydraTECH CBD

Lexaria just released the most important results yet from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s patented DehydraTECH(TM)-processed CBD on blood pressure Chris Bunka, Lexaria’s CEO, termed the results as “statistically significant” Participants in the study reported up to an average 23% decrease in blood pressure and a 7% drop in systolic pressure These results bring Lexaria closer to NDA filing with the FDA, making it a pioneer in CBD hypertension treatment  Lexaria Bioscience (NASDAQ: LEXX) just released the most recent results from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s…

Continue Reading

WednesdaySep 15, 2021 2:36 pm

Flora Growth Corp. (NASDAQ: FLGC) Receives its 2021 Commercial Export Quota Allocation from Colombian Government; Partners to Optimize Its Supply Chain By Implementing Global Cannabis Product Validation and Authentication Platform

Flora also recently announced it had received its 2021 commercial export quota allocation of 7,900 kilograms to cultivate, process, and distribute high-THC cannabis Flora Growth also announced it has entered into an agreement with Applied DNA Sciences, Inc. and TruTrace Technologies, Inc.  FLGC will deploy the two companies’ integrated technology as part of its global cannabis product validation and authentication platform The integrated technology will tag, test, and track Flora’s cannabis and cannabis derivative products during transit across an international supply chain, providing enhanced transparency, traceability, and trust As an internationally focused company, Flora Growth (NASDAQ: FLGC) has always strived…

Continue Reading

WednesdaySep 15, 2021 12:44 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Great Strides Toward Filing IND Application for Patented DehydraTECH(TM) Technology

Lexaria has begun the formal process of preparing an application for Investigational New Drug status for DehydraTECH(TM) and cannabidiol for hypertension The filing is being done with the assistance of an outside consultancy group, with Lexaria Bioscience designing non-clinical, clinical, and related product development required prior to the filing – all of which support Lexaria’s more ambitious goals There have been two successful human hypertension trials done with the combination DehydraTECH-CBD therapy in 2021, following an original human clinical study in 2018, and many animal studies Lexaria is making a strong case to support the efficacy of the technology for…

Continue Reading

MondaySep 13, 2021 3:02 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Impressive Blood Pressure Reduction in Hypertension Clinical Trials

Lexaria Bioscience has developed a patented technology that improves the bioavailability of pharmaceuticals and therapeutics in part by bypassing first-pass-liver processing Lexaria’s patented DehydraTECH (TM) technology is undergoing human clinical trials this year to determine its effectiveness in making cannabidiol (“CBD”) effective as a means of reducing blood pressure for high blood pressure patients The initial results of the first human clinical study showed the DehydraTECH-CBD compound was well tolerated by patients without troubling side effects and that the compound outperformed generic CBD controls Just-released initial (partial) results regarding the compound’s second human clinical trial show that a three-dose regimen…

Continue Reading

HempWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722